A Potential Role for B-Cell Activating Factor in the Pathogenesis of Autoimmune Myasthenia Gravis

Authors:
  • RLRobert Lisak
    Robert Lisak
  • RLRichard Lewis
    Richard Lewis
  • GSGregory Van Stavern
    Gregory Van Stavern
  • FGFelicitas Gonzales
    Felicitas Gonzales
  • KSKirk Simon
    Kirk Simon

Abstract
Autoimmune myasthenia gravis (MG) is a B cell–mediated disease in which the target autoantigen is the acetylcholine receptor (AChR) at the neuromuscular junction.1 Most patients with generalized symptoms have circulating anti-AChR antibodies. Some patients who are seronegative for anti-AChR antibodies have circulating antibodies to muscle-specific kinase (MuSK).2,3 The AChR-directed antibodies can bind to the various subunits of the AChR; however, most are specific for the α subunit.4 There is no correlation between the serum antibody titer and disease severity in MG.5 The inductive signals that lead to the breakdown of immune tolerance to the AChR remain unknown.

This publication has 23 references indexed in Scilit: